Current Partner Studies

Lupus Therapeutics has been involved in some of the most important breakthroughs in lupus research and is helping to guide future breakthroughs.

Historical/Completed Studies

Study Name: RIFLE

Phase 4, SLE

21 LuCIN sites (U.S. and Canada)

Study Name: Janssen LOTUS

Phase 3, SLE

27 LuCIN sites (U.S. and Canada)

Study Name: BMS Paisley SLE

Phase 2, SLE

21 LuCIN sites (U.S. and Canada)

Study Name: AMG570

Phase 2, SLE

16 LuCIN sites (U.S. and Canada)

Study Name: AMG592

Phase 2b, SLE

10 LuCIN sites (U.S. and Canada)

Study Name: Celgene CC-220

Phase 2, SLE

22 LuCIN sites (U.S. and Canada)

Study Name: EMD Serono M2591

Phase 2, SLE

8 LuCIN sites (U.S. and Canada)

Study Name: Lilly BT01

Phase 2, SLE

4 LuCIN sites (U.S. and Canada)

Study Name: Lilly ISLAND SLE (KFAJ)

Phase 2, SLE

15 LuCIN sites (U.S. and Canada)

Study Name: VIB7734 RECAST SLE

Phase 2, SLE

7 LuCIN sites (U.S. and Canada)

Study Name: Janssen Orchid

Phase 2, LN

6 LuCIN sites (U.S. and Canada)

Study Name: BMS Paisley LN

Phase 2, LN

18 LuCIN sites (U.S. and Canada)

Study Name: TAK-079

Phase 1b, SLE

10 LuCIN sites (U.S. and Canada)

Study Name: Aker-ORKIDS

Phase NA, SLE

22 LuCIN sites (U.S. and Canada)

Study Name: DIVINE

Phase NA, LN

7 LuCIN sites (U.S. and Canada)

Study Name: VALUE

Phase NA, SLE

10 LuCIN sites (U.S. and Canada)